Converse to KMT2A-rearranged AML, KMT2A-PTD enhances self-renewal of hematopoietic stem cells by blocking the cell differentiation but is not sufficient by itself to induce overt leukemia. The gene discussed is BCS1L; the disease is acute myeloid leukemia.